Fulcrum Therapeutics, Inc.
Every calculator, already run for FULC
Open the full toolkit →You have the numbers on FULC. Get the argument.
A written report on which of these readings actually decide the outcome for Fulcrum Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
5 analysts covering FULCAnalyst Price Target Disagreement for Fulcrum Therapeutics, Inc.
Wall Street's bull case implies +6% from the current price; the bear case implies -20%. Analysts are relatively aligned on FULC's range.
Ownership & short interest
Insider Trading Activity for FULC
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use pate…
FULC — frequently asked
Is FULC a buy right now?
Wall Street's consensus rating on Fulcrum Therapeutics, Inc. is Hold across 5 analysts, with a mean price target of $3.67 (-2% vs. the current $3.76). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is FULC's next earnings date?
Fulcrum Therapeutics, Inc. is next scheduled to report earnings around Oct 29, 2026. A full FULC research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Fulcrum Therapeutics, Inc.?
Analysts covering Fulcrum Therapeutics, Inc. (FULC) range from a bear-case target of $3.00 to a bull-case high of $4.00, with a mean consensus target of $3.67 across 3 analysts. The spread of $1.00 (27% of the current price) indicates moderate disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Fulcrum Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Fulcrum Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full FULC research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Fulcrum Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.